Claudia Piona

@univr.it

Dipartimento di Scienze Chirurgiche, Odontostomatologiche e Materno-Infantili
University of Verona

Claudia Piona


            Download Compact PDF  
https://researchid.co/pionaclaudia

RESEARCH, TEACHING, or OTHER INTERESTS

Pediatrics, Perinatology and Child Health, Endocrinology, Diabetes and Metabolism
81

Scopus Publications

Scopus Publications

  • High LDL-cholesterol in children and adolescents with type 1 diabetes: the impact of body adiposity and sex
    Claudio Maffeis, Elisa Morotti, Erika Caiazza, Quincy Pedranzini, Antonella Soglia, Parto Kharazizadeh, Marco Marigliano, Claudia Piona
    Nutrition Metabolism and Cardiovascular Diseases, 2026
  • Screening Programs for Type 1 Diabetes in Youth: Evidence for Clinical Practice
    Roberto Franceschi, Enza Mozzillo, Marco Marigliano, Giulio Maltoni, Ernesto Maddaloni, Rocco Amendolara, Luca Bernardini, Riccardo Bonfanti, Federica Ciambrelli, Francesca Di Candia, Ludovica Fedi, Alessandro Fierro, Dario Iafusco, Antonio Iannilli, Letizia Leonardi, Claudio Maffeis, Evelina Maines, Riccardo Pertile, Claudia Piona, Ivana Rabbone, Sara Santarelli, Carlo Ripoli, Andrea Scozzarella, Valentina Tiberi, Raffaella Buzzetti, Valentino Cherubini
    Pediatrics, 2026
    Studies of individuals at risk for developing type 1 diabetes (T1D) have demonstrated that the disease is a continuum that progresses sequentially through distinct identifiable stages before the onset of symptoms. Screening for islet antibodies (IAbs) in at-risk children for T1D (first-degree relatives or those with human leukocyte antigen genetic risk) and in the general population is becoming increasingly common in some countries. The main aim of the T1D screening program is to reduce rates of diabetic ketoacidosis (DKA) at diagnosis and to participate in research protocols that receive T1D-modifying therapies to delay clinical onset. These advantages are generally balanced with the psychological symptoms (such as anxiety and depression) that this information could produce in healthy children-adolescents and their parents, and the costs of the screening. Optimal ages for performing IAb screening in the general population have been established by cohort analyses in several studies. Primary care physicians can be responsible for family enrollment and capillary blood sampling in the general population. For follow-up of individuals who screen positive for IAbs, both age and the number of IAbs detected influence how frequently and intensively monitoring is recommended, as well as whether referral to a specialist care center is advised. Measures considered for monitoring include IAbs, hemoglobin A1c, random blood glucose, oral glucose tolerance test (OGTT), and continuous glucose monitoring (CGM). This article describes how such evidence has been implemented in Italy, offering practical insights into integrating screening into routine pediatric care.
  • Impact of screening programmes for type 1 diabetes in youth: A systematic review and meta-analysis
    Roberto Franceschi, Enza Mozzillo, Marco Marigliano, Giulio Maltoni, Ernesto Maddaloni, Rocco Amendolara, Luca Bernardini, Riccardo Bonfanti, Federica Ciambrelli, Francesca Di Candia, Ludovica Fedi, Alessandro Fierro, Dario Iafusco, Antonio Iannilli, Letizia Leonardi, Claudio Maffeis, Evelina Maines, Riccardo Pertile, Claudia Piona, Ivana Rabbone, Carlo Ripoli, Andrea Scozzarella, Valentina Tiberi, Raffaella Buzzetti, Valentino Cherubini
    Diabetic Medicine, 2026
    Aim To evaluate the impact of anti‐islet antibody (IAb) screening on the general population and first‐degree relatives (FDRs)/high‐risk individuals and evidence‐based follow‐up modalities. Methods We performed this review through systematic searches of PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov and International Clinical Trials Registry Platform between 15 March 2006, and 15 March 2025. We selected studies on children and adolescents screened for T1D IAbs, compared with people who were not screened or IAb+ individuals who were not followed up. PICOS framework was used in the selection process. Outcome data were extracted, and a meta‐analysis of DKA risk at T1D onset was performed. Quality of evidence was assessed using the GRADE approach. This study was registered with PROSPERO, CRD42024523781. Results Sixty‐six studies, 53 of moderate‐to‐high quality, were included. Screening was associated with lower DKA rates by 23% (95% CI 18–29%, I 2 = 88.8%). The risk of stage 3 T1D progression was high in younger children with persistent and/or multiple IAb+. Screening was associated with higher indicators of parental anxiety, which decreased during follow‐up. Children with IAb positivity were monitored according to age and T1D stage, using HbA1c, oral glucose tolerance testing and continuous glucose monitoring (CGM). Time above 140 mg/dL was a biomarker of progression. Conclusions Population screening with IAbs and follow‐up of IAb+ individuals helps decrease DKA and allows participation in intervention trials. This systematic review provides evidence for clinical practice on the screening timing, modalities and follow‐up. Further studies on the use of CGM are expected.
  • Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth
    Francesca Di Candia, Francesco Maria Rosanio, Roberto Franceschi, Alessandro Fierro, Riccardo Bonfanti, Francesca Cardella, Valentino Cherubini, Giuseppe D’Annunzio, Barbara Felappi, Dario Iafusco, Brunella Iovane, Claudio Maffeis, Giulio Maltoni, Francesca Olivieri, Gabriele Olivieri, Barbara Piccini, Elvira Piccinno, Barbara Predieri, Ivana Rabbone, Maria Rossella Ricciardi, Giuseppina Salzano, Riccardo Schiaffini, Gianluca Tornese, Angela Zanfardino, Marco Marigliano, Riccardo Troncone, Riccardo Pertile, Luigi Greco, Renata Auricchio, Enza Mozzillo, , Francesco Gallo, Caterina Grosso, Carlo Ripoli, Fiorella De Berardinis, Susanna Coccoli, Valentina Tiberi, Sonia Toni, Maurizio Delvecchio, Rosanna Roppolo, Fortunato Lombardo, Stefano Passanisi, Bruno Bombaci, Alberto Casertano, Nicola Minuto, Marta Bassi, Evelina Maines, Silvia Savastio, Elena Inzaghi, Andrea Rigamonti, Giulio Frontino, Patrizia Bruzzi, Claudia Piona
    Journal of Clinical Endocrinology and Metabolism, 2026
    Context Anti-transglutaminase antibodies (anti-TTG IgA) titer is associated with mucosal damage in celiac disease (CD). Objective The primary focus was to correlate anti-TTG IgA titer, HbA1c when CD occurs (HbA1cCD), and Marsh grade in children and adolescents with type 1 diabetes (T1D) at the time of CD diagnosis. As secondary outcomes, we assessed the optimal anti-TTG IgA upper limit of normal (ULN) cutoff for sparing biopsy, and personal and familial autoimmunity history in the individuals with T1D and CD (T1D-CD) compared with T1D-only. Methods In this retrospective observational study, among 6933 individuals with T1D onset (2010-2019), 556 were grouped according to CD onset: before (CD_FIRST), concomitant (CD_CONCOMITANT), or after T1D (T1D_FIRST), and compared with 141 T1D without CD. Measures included HbA1cCD, fold-anti-TTG IgA, anti-TTG IgA cutoff, and autoimmunity history of both groups, as well as Marsh grade in T1D-CD. Results In youths with T1D, HbA1cCD was associated with increased fold-anti-TTG IgA (Spearman r = 0.14, P = .0047). The optimal anti-TTG IgA cutoff for sparing biopsy was 11 ULN. Autoimmunity was prevalent in T1D-CD individuals, who showed more comorbidities than controls (χ2 25.4, P < .001), particularly the CD_FIRST (P < .001). Conclusion In children with T1D-CD, worse glucometabolic control is associated with an increase in fold anti-TTG IgA and with worse Marsh grade. A slightly higher anti-TTG IgA cutoff may be necessary for sparing biopsy compared to children in the general population. Higher prevalence of autoimmune comorbidities in CD_FIRST suggests that screening for T1D in the CD population should be mandatory.
  • Relationship between body adiposity and glycemic control in children and adolescents with type 1 diabetes
    Claudio Maffeis, Ilaria Fierri, Elisa Morotti, Erika Caiazza, Quincy Pedranzini, Marco Marigliano, Claudia Piona
    Acta Diabetologica, 2026
    Aims To investigate the relationship between body adiposity and glycemic control in children and adolescents with type 1 diabetes (T1D). Methods This cross-sectional study included 364 children and adolescents aged 6–18 years with T1D. Anthropometric indices [BMI, BMI Z-score, waist-to-height ratio (WHtR)] and body composition [fat mass (FM), FM%, fat mass index (FMI)], assessed using bioelectrical impedance analysis, were obtained. Hemoglobin A1c and glucose sensor metrics, including time in range (TIR), were used to assess glycemic control. Associations between variables were analyzed using Spearman’s correlation. Logistic regression models were run to identify independent predictors of HbA1c < 7.0% and TIR > 70%, with FMI, WHtR, total daily insulin dose per kg (TDD), treatment modalities, sex, age, diabetes duration, and pubertal stage as independent variables. Results Adiposity measures (FMI, FM%, and WHtR) were positively associated with HbA1c and negatively with TIR in both sexes. Logistic regression showed that HbA1c < 7% and TIR > 70% were significantly predicted by FMI [OR(95%CI): 0.822(0.704–0.960), p = 0.013, and 0.807(0.681–0.955), p = 0.012, respectively] and WHtR(x100) [OR(95%CI): 0.927(0.874–0.983), p = 0.013, and 0.923(0.866–0.985), p = 0.015, respectively], independently of TDD, sex , treatment modalities and the other independent variables. Conclusions Body adiposity negatively impacts glycemic control in children and adolescents with T1D, independent of sex and insulin treatment modalities. Despite technological advances in diabetes care, excess adiposity is emerging as a key modifiable factor associated with poorer glycemic outcomes and, consequently , poorer long-term health in children and adolescents with T1D.
  • Optimal age, duration of diabetes and frequency of screening for diabetic nephropathy in children and youths with type 1 Diabetes: A systematic review
    Stefano Passanisi, Claudia Piona, Valentina Mancioppi, Louise Puli, Kim C. Donaghue
    Diabetes Research and Clinical Practice, 2026
    Diabetic nephropathy (DN) is a major complication of type 1 diabetes (T1D) with lifelong health implications. This systematic review evaluated the optimal age, duration of diabetes, and frequency for DN screening in children and adolescents with T1D. A comprehensive literature search (1995-2024) across major databases identified 36 eligible studies, predominantly cross-sectional, encompassing 21,778 participants. Moderate albuminuria prevalence was 9.5 % overall, with most cases occurring after seven years of diabetes duration and in individuals older than 14 years, though rare cases were reported as early as 8.5 years and within two years of diagnosis. Severe albuminuria was less frequent (0.3-14.6 %), while end-stage kidney disease was rare, and no deaths were reported. Higher HbA1c levels (≥9%) were strongly associated with increased nephropathy risk, whereas limited data were available on blood pressure and other risk factors. No randomized trials or direct comparisons of screening strategies were identified, and heterogeneity in definitions and diagnostic methods limited evidence quality. Overall, findings support current international guidelines recommending screening from age 11 or puberty after 2-5 years of T1D duration, with intensified strategies potentially warranted for those with elevated HbA1 levels. High-quality, prospective studies are needed, especially in low- and middle-income countries.
  • Screening practices for diabetic peripheral neuropathy in pediatric type 1 diabetes: a nationwide survey by the ISPED Diabetes Study Group
    Bruno Bombaci, Marta Bassi, Valeria Castorani, Francesca Di Candia, Marta Ferrari, Mariangela Martino, Luca Zagaroli, Marco Marigliano, Riccardo Bonfanti, Diabetes Study Group of the Italian Society of Pediatric Endocrinology, Diabetology, Claudia Accursia Albino, Monica Aloe, Maria Teresa Anzelotti, Claudia Arnaldi, Fabrizio Barbetti, Marta Bassi, Maria Giulia Berioli, Luca Bernardini, Enrica Bertelli, Martina Biagioni, Adriana Bobbio, Bruno Bombaci, Riccardo Bonfanti, Clara Bonura, Giulia Patrizia Bracciolini, Mariella Bruzzese, Patrizia Bruzzi, Pietro Buono, Piera Buscarino, Francesco Cadario, Valeria Calcaterra, Elena Calzi, Marco Cappa, Roberta Cardani, Francesca Cardella, Giuliana Marcella Cardinale, Alberto Casertano, Valeria Castorani, Vittoria Cauvin, Valentina Cenciarelli, Franco Ceruti, Valentino Cherubini, Francesco Chiarelli, Giovanni Chiari, Stefano Cianfarani, Mario Cicchetti, Paola Cipriano, Dante Cirillo, Felice Citriniti, Maria Susanna Coccioli, Santino Confetto, Giovanna Contreas, Anna Coro, Antonella Correddu, Elisa Corsini, Antonino Crino′, Giuseppe d′Annunzio, Fiorella De Berardinis, Valeria De Donno, Gianpaolo De Filippo, Rosaria De Marco, Luisa De Sanctis, Elisabetta Del Duca, Maurizio Delvecchio, Annalisa Deodati, Procolo Di Bonito, Francesca Di Candia, Elena Faleschini, Valentina Fattorusso, Anna Favia, Giovanni Federico, Barbara Felappi, Mara Ferrari, Lucia Ferrito, Graziella Fichera, Franco Fontana, Elena Fornari, Roberto Franceschi, Francesca Franco, Adriana Franzese, Anna Paola Frongia, Giulio Frontino, Alberto Gaiero, Sabrina Maria Galassi, Francesco Gallo, Luigi Gargantini, Elisa Giani, Anna Jolanda Gortan, Vanna Graziani, Caterina Grosso, Antonella Gualtieri, Monica Guasti, Lucia Paola Guerraggio, Chiara Guzzetti, Dario Iafusco, Gennaro Iannicelli, Maria Laura Iezzi, Maria Giovanna Ignaccolo, Stefania Innaurato, Elena Inzaghi, Brunella Iovane, Lorenzo Iughetti, Peter Kaufmann, Alfonso La Loggia, Anna Giulia Lambertini, Rosa Lapolla, Anna Lasagni, Nicola Lazzaro, Pietro Lazzeroni, Lorenzo Lenzi, Riccardo Lera, Gabriella Levantini, Marilea Lezzi, Rosanna Lia, Alice Liguori, Donatella Lo Presti, Fortunato Lombardo, Antonella Lonero, Silvia Longhi, Antonella Lorubbio, Sonia Lucchesi, Rosella Maccioni, Maddalena Macedoni, Patrizia Cristiana Macellaro, Simona Filomena Madeo, Claudio Maffeis, Benedetta Mainetti, Giulio Maltoni, Chiara Mameli, Francesco Mammì, Maria Luisa Manca Bitti, Valentina Mancioppi, Melania Manco, Marco Marigliano, Monica Marino, Alberto Marsciani, Maria Cristina Matteoli, Elena Mazzali, Marta Minute, Nicola Minuto, Sara Monti, Anita Morandi, Gianfranco Morganti, Elisa Morotti, Enza Mozzillo, Gianluca Musolino, Francesca Olivieri, Federica Ortolani, Valentina Pampanini, Daniela Pardi, Filomena Pascarella, Bruno Pasquino, Stefano Passanisi, Ippolita Patrizia Patera, Annalisa Pedini, Maria Cristina Pennati, Sonia Peruzzi, Paola Peverelli, Giulia Pezzino, Barbara Piccini, Elvira Eugenia Rosaria Piccinno, Claudia Piona, Gavina Piredda, Alessia Piscopo, Carmelo Pistone, Erica Pozzi, Elena Prandi, Barbara Predieri, Sabrina Prudente, Anna Pulcina, Ivana Rabbone, Emioli Randazzo, Novella Rapini, Petra Reinstadler, Sara Riboni, Maria Rossella Ricciardi, Andrea Rigamonti, Carlo Ripoli, Virginia Rossi, Paolo Rossi, Irene Rutigliano, Alberto Sabbion, Alessandro Salvatoni, Caterina Salvo, Giuseppina Salzano, Mariateresa Sanseviero, Silvia Savastio, Rosanna Savini, Mariapiera Scanu, Andrea Enzo Scaramuzza, Riccardo Schiaffini, Maurizio Schiavone, Eleonardo Schieven, Mirella Scipione, Andrea Secco, Francesca Silvestri, Giulia Siri, Paola Sogno Valin, Silvia Sordelli, Daniele Spiri, Stefano Stagi, Filomena Andreina Stamati, Tosca Suprani, Valentina Talarico, Valentina Tiberi, Tiziana Antonia Lucia Timpanaro, Davide Tinti, Antonina Tirendi, Letizia Grazia Tomaselli, Sonia Toni, Cataldo Torelli, Gianluca Tornese, Michela Trada, Adolfo Andrea Trettene, Stefano Tumini, Marilena Tumminelli, Giuliana Valerio, Sara Vandelli, Claudia Ventrici, Maria Zampolli, Manuela Zanatta, Angela Zanfardino, Clara Zecchino, Silvia Zonca, Stefano Zucchini
    Acta Diabetologica, 2026
  • Managing Children and Adolescents with Type 1 Diabetes and Coexisting Celiac Disease: Real-World Data from a Global Survey
    Maja Raicevic, Francesco Maria Rosanio, Tiago Jeronimo Dos Santos, Agata Chobot, Claudia Piona, Laura Cudizio, Hussain Alsaffar, Katja Dumic, Sommayya Aftab, Meera Shaunak, Enza Mozzillo, Rade Vukovic, and
    Hormone Research in Paediatrics, 2025
    <b><i>Introduction:</i></b> Celiac disease (CD) is among the diseases most commonly associated with type 1 diabetes (T1D). This study aimed to evaluate the worldwide practices and attitudes of physicians involved in pediatric diabetes care regarding diagnosing and managing CD in children with T1D. <b><i>Methods:</i></b> The 30-item survey was conducted between July and December 2023 aimed at targeting pediatricians with special interest in T1D and CD. It was shared by the JENIOUS – young investigators group of the International Society of Pediatric and Adolescent Diabetes (ISPAD) – and the YES – early career group of the European Society for Pediatric Endocrinology (ESPE). <b><i>Results:</i></b> Overall, 180 physicians (67.8% female) from 25 countries responded. Among respondents, 62.2% expected sustaining optimal glycemic control in children with T1D and CD (T1D + CD) to be more difficult than in children with T1D alone. Majority (81.1%) agreed that more specific guidelines are needed. The follow-up routine for patients with T1D + CD differed, and one-quarter of physicians scheduled more frequent follow-up checkups for these patients. Seventy percent agreed multidisciplinary outpatient clinics for their follow-up is needed. In the multivariate ordinal logistic regression model, a statistically significant predictor of a higher degree of practice according to ISPAD 2022 guidelines was a higher level of country income (OR = 3.34; <i>p</i> < 0.001). <b><i>Conclusions:</i></b> These results showed variations in physicians’ practices regarding managing CD in children with T1D, emphasizing the need for more specific guidelines and intensive education of physicians in managing this population, especially in lower-income countries. Our data also suggest the implementation of multidisciplinary outpatient clinics for their follow-up.
  • Initial observations on the frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population
    Valentino Cherubini, Andrea Enzo Scaramuzza, Umberto Agrimi, Riccardo Bonfanti, Emanuele Bosi, Antonio D'Avino, Dario Iafusco, Marco Marigliano, Enza Mozzillo, Flavia Pricci, Ivana Rabbone, Carlo Ripoli, Marco Silano, Francesca Ulivi, Olimpia Vincentini, Rosaria Gesuita, and
    Diabetes Obesity and Metabolism, 2025
    Diabetic ketoacidosis (DKA) is common at clinical onset of diabetes,1 and a delayed diabetes diagnosis is a major contributing factor.2 Following parliament approval in September 2023 and endorsement by the Italian Paediatric Society (SIP) and the Italian Society of Paediatric Endocrinology and Diabetology (ISPED),3 Italy became the first country to legislate for voluntary screening for type 1 diabetes and celiac disease (law no. 130/23 proposed by the Fondazione Italiana Diabete stating, as a public health measure, universal screening for type 1 diabetes and celiac disease in children). This initiative aims to reduce the incidence of DKA, slow diabetes progression, and diagnose celiac disease earlier. A 2024 pilot study conducted in four Italian regions (Lombardy, Marche, Campania, Sardinia), dubbed the ‘D1Ce (Diabetes type 1 and Celiac disease) Screen Study’, evaluated the feasibility of general population screening for these conditions by collecting clinical data, conducting widespread screening, and communicating results to families. Positive cases were referred to specialized centres for further monitoring and treatment. However, these regions were engaged in D1Ce Screen in 2023 before project implementation in 2024 through multiple stakeholder participation, including from the Ministry of Health, the Istituto Superiore di Sanità (ISS), experts in type 1 diabetes and celiac disease, laboratories, family paediatricians, and specialized paediatric diabetes and celiac disease centres. Family paediatricians in the regions selected for D1Ce Screen played a vital role in implementation by informing families about the screening process. In this pre-implementation phase in 2023, several online and in-person meetings were organized with paediatricians in the involved regions focusing on the importance of early diagnosis of type 1 diabetes, DKA prevention, and the potential of offering diabetes-modifying therapies. In addition, the ISS established an IT platform providing video tutorials and electronic educational materials for children and parents.4 To investigate the impact of the D1Ce Screen project, here we compared the frequency of DKA in regions involved in the D1Ce Screen project with the frequency in regions not involved in the project, evaluating data in the year before D1Ce Screen implementation (2023) and in 2024, when screening was implemented. In January 2025, we conducted a survey of Italian paediatric diabetes centres to analyse DKA frequency at diagnosis of type 1 diabetes in 2023 and 2024. We collected aggregated data on children and adolescents categorised by age group (0.5–5, 6–11, and 12–17 years) together with their sex, presence of DKA or severe DKA at diagnosis (defined as per ISPAD guidelines: blood glucose >11 mmol/L (200 mg/dL), venous pH <7.3 or bicarbonate <15 mmol/L, and ketonaemia/ketonuria for DKA and venous pH <7.1 or bicarbonate <5 mmol/L for severe DKA), and year of observation. All type 1 diabetes diagnoses were confirmed by the presence of at least one autoantibody targeting pancreatic islet cells. The proportion of DKA in the population of children and adolescents with newly diagnosed type 1 diabetes was estimated as the ratio of new type 1 diabetes cases with DKA at onset and the number of new type 1 diagnoses with 95% confidence intervals (95% CI) stratified by age group, sex, year of observation, and by regions participating in D1Ce Screen in 2024 (Lombardia, Marche, Campania, Sardegna) and those not involved in the project (Abruzzo, Calabria, Emilia-Romagna, Friuli, Lazio, Liguria, Piemonte, Sicilia, Toscana, Puglia, Trentino, and Veneto). The study was conducted in accordance with the Helsinki Declaration, and all data were anonymised. Ethics committee approval was not required, since the General Authorisation to Process Personal Data for Scientific Research Purposes (authorisation 9/2014) exempts retrospective archive studies that use identifier codes preventing subject re-identification. Two logistic regression models were constructed to assess factors associated with DKA or severe DKA at onset, with year of observation, sex, age group, and involved/uninvolved regions and second-order interaction terms as explanatory variables. Results are reported as forest plots with odds ratios (OR) and 95% CIs. The likelihood ratio (LR) test and Hosmer–Lemeshow test were used to select the most parsimonious model and to evaluate the model's goodness of fit. Fifty-eight of 59 Italian paediatric diabetes centres participated in the study, following a median (IQR) of 150 (87–426) children and adolescents in each centre. Over the 2-year observation period, 2398 children and adolescents under 18 years were diagnosed with type 1 diabetes. DKA and severe DKA (as a subset of DKA cases) were observed in 821 cases (34.2%, 95% CI: 32.3–36.2) and 316 cases (13.2%, 95% CI: 11.9–14.6), respectively. New cases of type 1 diabetes and proportion of DKA at diagnosis by year of onset, age group, and included/not included region are reported in Table 1. Percentages of DKA and severe DKA at diagnosis of type 1 diabetes by age group and year of diagnosis are shown in Figure S1. DKA and severe DKA were more common in regions not involved in the D1Ce Screen project than in those not involved in the project in both 2023 (DKA OR 0.76, 95% CI: 0.60–0.97; severe DKA OR 0.46, 95% CI: 0.31–0.68) and 2024 (DKA OR 0.69, 95% CI: 0.53–0.90; severe DKA OR 0.55, 95% CI: 0.37–0.81). There were no significant differences in DKA or severe DKA frequencies over the 2 years of observation in participating and non-participating regions or the entire population. With year of observation, sex, age group, and involved/uninvolved regions included as explanatory variables, logistic regression models showed that the odds of DKA were 26% lower (OR 0.74, 95% CI: 0.62–0.88, p < 0.001) and the odds of severe DKA were 49% lower (OR 0.51, 95% CI: 0.39–0.67, p < 0.001) in regions involved in the D1Ce Screen project than in non-participating regions, respectively (Figure 1, Table S1). The probability of DKA was significantly higher in the two younger age groups than in the two older ones; no differences were observed in terms of year of onset and sex for both DKA and severe DKA. The D1Ce Screen project marks the first step in the implementation of the diabetes screening law in Italy. Here we report preliminary results of this initiative. Individuals in regions involved in the project were 26% less likely to present with DKA at diagnosis of type 1 diabetes and 49% less likely to present with severe DKA. The reduced risk of DKA was apparent both in 2023, when the D1Ce Screen project was being planned and discussions with important stakeholders such as family paediatricians had already begun, and in 2024, when the pilot project started in earnest. Therefore, the observed reduced risk of DKA at diagnosis in the D1Ce Screen regions cannot be attributed to the direct results of screening (i.e., autoantibody detection), as the effect was seen in 2023 before pilot program implementation and before positive autoantibody results were being communicated to affected individuals and their families. In addition, this study shows that, in 2023 and 2024, there was a slight reduction in DKA in Italy (about 18%) compared with recent observations.5, 6 This study aimed to provide an early assessment of the potential direct impact of screening by comparing regions actively participating in the D1Ce Screen pilot project in 2024 with those not participating, using 2023 data from both regions as baseline. To achieve this, our multiple logistic regression model (Figure 1, Table S1) included the year of observation and region involvement as explanatory variables, allowing us to evaluate whether there were independent effects of year and region on DKA occurrence. These results show that, over this period of observation, there was no observable direct effect from D1Ce Screen implementation in this early and limited phase of the initiative. This study was not intended to assess the determinants of changes in DKA frequency but to explore effects potentially related to the first phase of implementation of type 1 diabetes screening. The early diagnosis of type 1 diabetes is crucial for preventing DKA,7 which is often caused by delays in diagnosis. The initial symptoms of type 1 diabetes, such as fatigue or increased thirst, can be non-specific or develop gradually, making it challenging to distinguish children with type 1 diabetes from the many who exhibit similar symptoms due to minor, undifferentiated illnesses. Common reasons for a delayed diagnosis include misdiagnosis by attributing symptoms to common illnesses and delays in the diagnostic and referral pathways before a child is seen by a specialist team.8 It is plausible to speculate that the active participation of family paediatricians from early 2023 onwards, as key players in the D1Ce Screen projects, may have been a significant factor in increasing their attention to the signs and symptoms of the disease and thus to the early diagnosis of type 1 diabetes, thus reducing the risk of DKA in these regions. It is also conceivable that there may have been a general increase in awareness about diabetes, including in paediatric diabetologists and paediatricians in regions not directly involved in the project but certainly aware of the new law. This could be one possible explanation for the broader, albeit non-significant, decrease in DKA across regions noted in our survey. If such a spillover awareness effect exists, it would indeed make the specific impact of the D1Ce interventions harder to isolate and could potentially lead to an underestimation of the true effect in participating regions when compared with non-participating regions that also experienced some awareness benefit. Recent systematic reviews9-11 have suggested that DKA incidence may be falling in some settings due to improved awareness and practitioner behaviour, though trends vary by region and methodological variability challenges definitive conclusions. In Italy, the 8-year Parma campaign was associated with a 78% decrease in DKA incidence,12 but that was a smaller local initiative compared with the current study. This survey was based on a very high participation of Italian paediatric diabetes centres (98%), providing a comprehensive overview of new diagnoses of type 1 diabetes across the country in light of the launch of the screening programme. However, as a preliminary observational study using aggregated data, we cannot definitively establish causality nor account for unintended confounding. While our approach adjusted for age, sex, year, and region participation, other unmeasured confounders such as healthcare access, population density, urban and rural disparity, general paediatrician education, national awareness campaigns, or COVID-related changes in health behaviour may have influenced the observed outcomes. ISPED now intends to monitor the effects of the screening programme on early-onset DKA through the longitudinal study of involved children and family paediatricians by examining a larger, unselected population and considering factors not collected here, such as the socioeconomic and demographic characteristics of participants. In conclusion, the introduction of screening for type 1 diabetes in clinical practice has the potential to reduce the frequency of DKA at type 1 diabetes diagnosis both by identifying individuals in presymptomatic phases and, as our early findings suggest, possibly by contributing to decreased DKA at clinical presentation through increased practitioner and general population awareness. This early snapshot of programme efficacy now needs assessing over the longer term and separating out from true screening effects. Valentino Cherubini, Andrea Enzo Scaramuzza and Ivana Rabbone conceptualized and designed the study, designed the data collection instrument, collected data, wrote the article and contributed to discussions. Riccardo Bonfanti, Dario Iafusco, Enza Mozzillo, Carlo Ripoli and Marco Marigliano supervised data collection and analysis and critically revised and reviewed the manuscript. Rosaria Gesuita performed statistical analysis, wrote the article and contributed to discussions. Umberto Agrimi, Emanuele Bosi, Antonio D'Avino, Flavia Pricci, Marco Silano, Francesca Ulivi and Olimpia Vincentini are members of the D1Ce study group and discussed critically the results and the final draft of the article. Members of Diabetes Study Group of the Italian Society for Paediatric Endocrinology and Diabetes collected data and discussed and commented on data analyses. Andrea Enzo Scaramuzza is the corresponding author of this work and, as such, had full access to all the data in the study and has final responsibility as guarantor. No funds have been received for conducting the present study. Open access publishing facilitated by Azienda Socio Sanitaria Territoriale di Cremona, as part of the Wiley – SBBL agreement. The authors declare no conflicts of interest. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.16611. Data are available upon reasonable request from the corresponding author. Figure S1. Percentage of DKA and severe DKA at type 1 diabetes diagnosis (and 95% CI) by age groups and year of diagnosis. Table S1. Factors associated with DKA or severe DKA at diagnosis of type 1 diabetes. Results of multiple regression analysis. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
  • Vascular Complications in Children and Young People with Type 1 Diabetes: A Worldwide Assessment of Diabetologists' Adherence to International Recommendations
    Claudia Piona, Agata Chobot, Tiago Jeronimo Dos Santos, Elisa Giani, M. Loredana Marcovecchio, Claudio Maffeis, Carine de Beaufort
    Hormone Research in Paediatrics, 2025
    &lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; This global survey evaluated the practices and adherence to international Clinical Practice Consensus Guidelines (CPCG) of physicians involved in pediatric diabetes care regarding screening, prevention and treatment of vascular complications of type 1 diabetes (T1D). &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; A web-based survey gathering data about respondents’ background, practices related to screening, prevention, and treatment of diabetic nephropathy, retinopathy, neuropathy, and macrovascular diseases and a self-assessment of physicians’ knowledge based on the ISPAD CPCG 2018 were shared by ISPAD. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We received 175 responses from 62 countries (60% female, median age 42.3 years, 72.0% ISPAD members). Two-thirds of respondents initiated nephropathy and retinopathy screening per CPCG recommendations. Only half of them adhered to recommendations for neuropathy and macrovascular disease risk factors (RFs). Over 85% of respondents used the recommended screening method for nephropathy, retinopathy and macrovascular disease RFs, and only 59% for neuropathy. Lack of access to neuropathy and macrovascular diseases RF screening methods was reported by 22.2% and 11.8% of respondents, respectively. Adherence to recommended screening frequency varied: 92% for nephropathy, around two-thirds for neuropathy and macrovascular disease RFs, and only 17.7% for retinopathy. Most participants aligned their practices for treating T1D complications with CPCG recommendations, except for nephropathy. Significant differences in adherence to CPCG and individuals’ financial contributions reflected countries' income levels. Around 50% of the respondents were very familiar with the ISPAD CPCG content. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Our study highlights global variation in adherence to CPCG for T1D vascular complications, which is influenced by country income and healthcare disparities. It also revealed knowledge gaps among physicians on this critical topic.
  • Increasing HbA1c in children and youth with a first-degree relative with type 1 diabetes predicts progression to diabetes: a single-centre 10-year screening experience
    Claudia Piona, Giovanna Contreas, Susanna Gobbi, Erika Caiazza, Costantini Silvia, Elisa Morotti, Marco Marigliano, Claudio Maffeis
    Acta Diabetologica, 2025
  • A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
    Elisa Danese, Claudia Piona, Mariateresa Rizza, Elena Tiziani, Laura Pighi, Elisa Morotti, Gian Luca Salvagno, Camilla Mattiuzzi, Claudio Maffeis, Giuseppe Lippi
    Diagnostics, 2025
  • Glycemic Control in Children and Adolescents with Type 1 Diabetes: From Challenges to Innovation
    Stefano Passanisi, Agata Chobot, Claudia Piona
    Children, 2025
  • First International Survey on Diabetes Providers’ Assessment of Skin Reactions in Youth With Type 1 Diabetes Using Technological Devices
    Stefano Passanisi, Anna Korsgaard Berg, Agata Chobot, Tiago Jeronimo Dos Santos, Claudia Anita Piona, Laurel Messer, Fortunato Lombardo, and
    Journal of Diabetes Science and Technology, 2025
  • Knowledge, Attitudes, and Practices in Neonatal Diabetes Mellitus Management: the JEnious-NeOnatal-DIabetes (JENODI) Survey
    Maurizio Delvecchio, Claudia Piona, Agata Chobot, Laura Cudizio, Asma Deeb, Nancy Elbarbary, Tiago J. Dos Santos, Abdelhadi Habeb, and
    Diabetes Therapy, 2025
  • A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass
    Claudia Piona, Enza Mozzillo, Antonella Tosco, Chiara Zusi, Federica Emiliani, Sonia Volpi, Francesca Di Candia, Valeria Raia, Maria Linda Boselli, Maddalena Trombetta, Marco Cipolli, Riccardo C Bonadonna, Claudio Maffeis
    Journal of Clinical Endocrinology and Metabolism, 2025
  • Glycemic Variability and Time in Range Are Associated with the Risk of Overweight and High LDL-Cholesterol in Children and Youths with Type 1 Diabetes
    Claudia Piona, Marco Marigliano, Valentina Mancioppi, Enza Mozzillo, Luisa Occhiati, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Maurizio Delvecchio, Stefano Passanisi, Fortunato Lombardo, Claudio Maffeis
    Hormone Research in Paediatrics, 2025
  • Hepatic lipogenesis marked by GCKR-modulated triglycerides increases serum FGF21 in children/teens with obesity
    Claudio Maffeis, Anita Morandi, Chiara Zusi, Francesca Olivieri, Elena Fornari, Paolo Cavarzere, Claudia Piona, Massimiliano Corradi, Federica Emiliani, Alessandro Da Ros, Roberto Berni Canani, Alessandro Mantovani, Giovanni Targher
    Diabetes Obesity and Metabolism, 2025
  • An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity
    Claudia Piona, Eleonora Maria Aiello, Valentina Mancioppi, Erika Caiazza, Francesca Olivieri, Stefano Passanisi, Fortunato Lombardo, Concetta Mastropasqua, Cosimo Giannini, Giuseppe Riccardi, Claudio Maffeis
    Diabetes Technology and Therapeutics, 2025
  • SKIN-PEDIC: A Worldwide Assessment of Skin Problems in Children and Adolescents Using Diabetes Devices
    Anna Korsgaard Berg, Stefano Passanisi, Thekla von dem Berge, Agata Chobot, Nancy Samir Elbarbary, Julie Pelicand, Franco S. Giraudo, Rosaline Mentink, Floris Levy-Khademi, Ana L. Creo, Malene Søborg Heidemann, Claudia Piona, Emrullah Arslan, Didem Gunes Kaya, Theo C.J. Sas, Lars Krogvold, Stefano Tumini, Cari Berget, Tiago Jeronimo Dos Santos, Beate Karges, Mariana Zorron, Jannet Svensson, and
    Hormone Research in Paediatrics, 2025
  • T1Drink: Education Gaps and Safety Issues Concerning Alcohol Consumption in Young Adults with Type 1 Diabetes Mellitus – A JENIOUS-Driven International Initiative Report
    Arkadiusz Michalak, Jędrzej Chrzanowski, Julia Wykrota, Nicole Blauensteiner, Jacek Burzyński, Antoni Blachnicki, Eren Er, Júlia Galhardo, Beata Mianowska, Deniz Özalp Kızılay, Vit Neuman, Julie Pelicand, Lukas Plachy, Barbara Pernak, Maja Raicevic, Marissa Town, Meng-Che Tsai, Thekla von dem Berge, Rade Vukovic, Sanja Panic Zaric, Agata Chobot, Elisa Giani, Claudia Piona, Tiago Jeronimo dos Santos, Wojciech Fendler, and
    Hormone Research in Paediatrics, 2025
  • Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
    Claudio Maffeis, Claudia Piona, Anita Morandi, Marco Marigliano, Elisa Morotti, Valentina Mancioppi, Erika Caiazza, Chiara Zusi, Federica Emiliani, Alessandro Mantovani, Antonio Colecchia, Giovanni Targher
    Diabetes Obesity and Metabolism, 2024
  • Variant reclassification over time decreases the level of diagnostic uncertainty in monogenic obesity: Experience from two centres
    Anita Morandi, Elena Fornari, Massimiliano Corradi, Giuseppina Rosaria Umano, Francesca Olivieri, Claudia Piona, Alice Maguolo, Carola Panzeri, Federica Emiliani, Grazia Cirillo, Paolo Cavarzere, Emanuele Miraglia Del Giudice, Claudio Maffeis
    Pediatric Obesity, 2024
  • Device-Related Skin Reactions Increase Emotional Burden in Youths With Type 1 Diabetes and Their Parents
    Stefano Passanisi, Francesca Galletta, Bruno Bombaci, Valentino Cherubini, Valentina Tiberi, Nicola Minuto, Marta Bassi, Dario Iafusco, Alessia Piscopo, Enza Mozzillo, Francesca Di Candia, Ivana Rabbone, Erica Pozzi, Roberto Franceschi, Vittoria Cauvin, Claudio Maffeis, Claudia Anita Piona, Giuseppina Salzano
    Journal of Diabetes Science and Technology, 2024
  • Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes
    Claudia Piona, Stefano Passanisi, Bruno Bombaci, Marco Marigliano, Fortunato Lombardo, Valentina Mancioppi, Anita Morandi, Claudio Maffeis, Giuseppina Salzano, and
    Diabetes Obesity and Metabolism, 2024
  • Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications
    Agata Chobot, Claudia Piona, Bruno Bombaci, Olga Kamińska-Jackowiak, Valentina Mancioppi, Stefano Passanisi
    Children, 2024
  • Are we ready to screen for type 1 diabetes? A structured worldwide survey among healthcare providers involved in paediatric diabetes care
    Vit Neuman, Claudia Piona, Laura Cudizio, Lenka Drnkova, Zdenek Sumnik, Matvei G. Slavenko, Michael J. Haller, David M. Maahs, Agata Chobot, and
    Diabetic Medicine, 2024
  • Skin Reactions in Children with Type 1 Diabetes Associated with the Use of New Diabetes Technologies—An Observational Study from a Regional Polish Pediatric Diabetes Center
    Ewa Ledwoń, Paula Zemła-Szten, Thekla von dem Berge, Krzysztof Nalewajko, Stefano Passanisi, Claudia Piona, Tiago dos Santos, Jannet Svensson, Anna Korsgaard Berg, Agata Chobot
    Children, 2024
  • Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study
    Stefano Passanisi, Giuseppina Salzano, Bruno Bombaci, Nicola Minuto, Marta Bassi, Riccardo Bonfanti, Francesco Scialabba, Enza Mozzillo, Francesca Di Candia, Sara Monti, Vanna Graziani, Claudio Maffeis, Claudia Anita Piona, Claudia Arnaldi, Davide Tosini, Barbara Felappi, Rosalia Roppolo, Angela Zanfardino, Maurizio Delvecchio, Donatella Lo Presti, Elena Calzi, Carlo Ripoli, Roberto Franceschi, Petra Reinstadler, Ivana Rabbone, Giulio Maltoni, Angela Alibrandi, Stefano Zucchini, Marco Marigliano, Fortunato Lombardo, , Caterina Grosso, Valentino Cherubini, Valentina Tiberi, Elvira Piccinno, Clara Zecchino, Elena Prandi, Maria Rossella Ricciardi, Filomena Stamati, Giuseppe Costanza, Giulia Pezzino, De Marco Rosaria, Anna Bratta, Giordano Spacco, Andrea Rigamonti, Giulio Frontino, Barbara Predieri, Dario Iafusco, Francesco Rosanio, Erica Pozzi, Francesca Cardella, Sara Dal Bo, Chiara Riso
    Diabetes Care, 2024
  • Glucose sensor with predictive alarm for hypoglycaemia: Improved glycaemic control in adolescents with type 1 diabetes
    Marco Marigliano, Claudia Piona, Valentina Mancioppi, Elisa Morotti, Anita Morandi, Claudio Maffeis
    Diabetes Obesity and Metabolism, 2024
  • Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities
    Stefano Passanisi, Claudia Piona, Giuseppina Salzano, Marco Marigliano, Bruno Bombaci, Anita Morandi, Angela Alibrandi, Claudio Maffeis, Fortunato Lombardo
    Diabetes Technology and Therapeutics, 2024
  • Recommendations for recognizing, risk stratifying, treating, and managing children and adolescents with hypoglycemia
    Stefano Zucchini, Stefano Tumini, Andrea Enzo Scaramuzza, Riccardo Bonfanti, Maurizio Delvecchio, Roberto Franceschi, Dario Iafusco, Lorenzo Lenzi, Enza Mozzillo, Stefano Passanisi, Claudia Piona, Ivana Rabbone, Novella Rapini, Andrea Rigamonti, Carlo Ripoli, Giuseppina Salzano, Silvia Savastio, Riccardo Schiaffini, Angela Zanfardino, Valentino Cherubini, and
    Frontiers in Endocrinology, 2024
  • Glycemia Risk Index as a Novel Metric to Evaluate the Safety of Glycemic Control in Children and Adolescents with Type 1 Diabetes: An Observational, Multicenter, Real-Life Cohort Study
    Claudia Piona, Marco Marigliano, Chiara Roncarà, Enza Mozzillo, Francesca Di Candia, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Elvira Piccinno, Maurizio Delvecchio, Stefano Passanisi, Fortunato Lombardo, Riccardo Bonfanti, Claudio Maffeis
    Diabetes Technology and Therapeutics, 2023
  • Cardiovascular Risk Factors in Children and Adolescents with Type 1 Diabetes Mellitus: The Role of Insulin Resistance and Associated Genetic Variants
    Alice Maguolo, Marco Rioda, Chiara Zusi, Federica Emiliani, Francesca Olivieri, Claudia Piona, Marco Marigliano, Silvia Orsi, Anita Morandi, Claudio Maffeis
    Hormone Research in Paediatrics, 2023
  • A new proposal for a second insulin bolus to optimize postprandial glucose profile in adolescents with type 1 diabetes
    Marco Marigliano, Claudia Piona, Francesca Tommaselli, Alice Maguolo, Anita Morandi, Claudio Maffeis
    Acta Diabetologica, 2023
  • Correction to: A new proposal for a second insulin bolus to optimize postprandial glucose profile in adolescents with type 1 diabetes (Acta Diabetologica, (2023), 60, 5, (609-618), 10.1007/s00592-022-02019-2)
    Marco Marigliano, Claudia Piona, Francesca Tommaselli, Alice Maguolo, Anita Morandi, Claudio Maffeis
    Acta Diabetologica, 2023
  • MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control
    Fortunato Lombardo, Stefano Passanisi, Angela Alibrandi, Bruno Bombaci, Riccardo Bonfanti, Maurizio Delvecchio, Francesca Di Candia, Enza Mozzillo, Elvira Piccinno, Claudia Anita Piona, Andrea Rigamonti, Francesco Scialabba, Claudio Maffeis, Giuseppina Salzano
    Diabetes Technology and Therapeutics, 2023
  • Risk factors for pre-clinical atherosclerosis in adolescents with type 1 diabetes
    Anita Morandi, Claudia Piona, Massimiliano Corradi, Marco Marigliano, Alice Giontella, Silvia Orsi, Federica Emiliani, Angela Tagetti, Denise Marcon, Cristiano Fava, Claudio Maffeis
    Diabetes Research and Clinical Practice, 2023
  • A retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump
    Maurizio Delvecchio, Alessio Galati, Claudio Maffeis, Stefano Passanisi, Riccardo Bonfanti, Roberto Franceschi, Gianluca Tornese, Elena Calzi, Angela Zanfardino, Giulia Patrizia Bracciolini, Elvira Piccinno, and
    Diabetes Obesity and Metabolism, 2023
  • Early marker of ocular neurodegeneration in children and adolescents with type 1 diabetes: the contributing role of polymorphisms in mir146a and mir128a genes
    Claudia Piona, Silvia Costantini, Chiara Zusi, Tiziano Cozzini, Emilio Pedrotti, Marco Marigliano, Elena Fornari, Alice Maguolo, Anita Morandi, Claudio Maffeis
    Acta Diabetologica, 2022
  • Markers of subclinical vascular damage in young adults with type 1 diabetes mellitus: the role of central blood pressure
    Denise Marcon, Angela Tagetti, Claudia Piona, Alice Giontella, Stefano Bortolotti, Sara Bonafini, Lorenza Carletti, Anita Morandi, Maddalena Trombetta, Claudio Maffeis, Cristiano Fava
    Journal of Hypertension, 2022
  • Uric acid and cardiometabolic risk by gender in youth with type 1 diabetes
    Procolo Di Bonito, Francesco Maria Rosanio, Maria Loredana Marcovecchio, Valentino Cherubini, Maurizio Delvecchio, Francesca Di Candia, Dario Iafusco, Angela Zanfardino, Brunella Iovane, Claudio Maffeis, Giulio Maltoni, Carlo Ripoli, Elvira Piccinno, Claudia Anita Piona, Maria Rossella Ricciardi, Riccardo Schiaffini, Adriana Franzese, Enza Mozzillo
    Scientific Reports, 2022
  • Proceedings of 21st ISPAD science school for physicians 2022
    Tiago Jeronimo dos Santos, Agata Chobot, Claudia Piona, Klemen Dovc, Torben Biester, Katarzyna Anna Gajewska, Carine de Beaufort, Zdenek Sumnik, Lenka Petruzelkova
    Pediatric Diabetes, 2022
  • Genetic Variation in Antioxidant Response Modulates the Level of Oxidative Stress in Youth with Type 1 Diabetes and Poor Glycemic Control
    Anita Morandi, Massimiliano Corradi, Chiara Zusi, Claudia Piona, Silvia Costantini, Marco Marigliano, Claudio Maffeis
    Antioxidants, 2022
  • Twenty years of the International Society for Pediatric and Adolescent Diabetes Science Schools programs: Assessment of their impact on the participants' personal careers and networking development
    Tiago Jeronimo Dos Santos, Agata Chobot, Wafaa Laimon, Sheridan Waldron, Claudia Piona, Elisa Giani, Klemen Dovc, Maddalena Macedoni, Chiara Mameli, Roque Cardona‐Hernandez, Bärbel Aschemeier‐Fuchs, Margaret McGill, Alan M. Delamater, Jamie Wood, Luís Eduardo Calliari, Andrea Scaramuzza, Carine De Beaufort, Sylvia Lion, Thomas Danne, Kim C. Donaghue, and
    Pediatric Diabetes, 2022
  • Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis
    Claudia Piona, Enza Mozzillo, Antonella Tosco, Sonia Volpi, Francesco Maria Rosanio, Chiara Cimbalo, Adriana Franzese, Valeria Raia, Chiara Zusi, Federica Emiliani, Maria Linda Boselli, Maddalena Trombetta, Riccardo Crocina Bonadonna, Marco Cipolli, Claudio Maffeis
    Journal of Clinical Medicine, 2022
  • Sex differences in cardiovascular risk factors of children and adolescents with type 1 diabetes mellitus: A role for diet?
    Claudio Maffeis, Francesca Olivieri, Paola Peverelli, Margherita Cendon, Francesca Tomasselli, Mara Tommasi, Tatiana Trandev, Elena Fornari, Claudia Piona, Anita Morandi, Alice Maguolo
    Nutrition Metabolism and Cardiovascular Diseases, 2022
  • A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes
    Roberto Franceschi, Enza Mozzillo, Francesca Di Candia, Francesco Maria Rosanio, Letizia Leonardi, Alice Liguori, Francesca Micheli, Vittoria Cauvin, Adriana Franzese, Claudia Anita Piona, M. Loredana Marcovecchio
    Acta Diabetologica, 2022
  • Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real-world cohort study
    Klemen Dovc, Michelle Van Name, Barbara Jenko Bizjan, Ewa Rusak, Claudia Piona, Gul Yesiltepe‐Mutlu, Rosaline Mentink, Giulio Frontino, Maddalena Macedoni, Sofia Helena Ferreira, Joana Serra‐Caetano, Júlia Galhardo, Julie Pelicand, Francesca Silvestri, Jennifer Sherr, Agata Chobot, Torben Biester, for the ISPAD JENIOUS Group
    Diabetes Obesity and Metabolism, 2022
  • High Glycemic Variability Is Associated with Worse Continuous Glucose Monitoring Metrics in Children and Adolescents with Type 1 Diabetes
    Claudia Piona, Marco Marigliano, Enza Mozzillo, Francesca Di Candia, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Maurizio Delvecchio, Claudio Maffeis
    Hormone Research in Paediatrics, 2022
  • Evaluation of HbA1c and glucose management indicator discordance in a population of children and adolescents with type 1 diabetes
    Claudia Piona, Marco Marigliano, Enza Mozzillo, Francesca Di Candia, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Elvira Piccinno, Claudio Maffeis
    Pediatric Diabetes, 2022
  • Long-term complications of type 1 diabetes: what do we know and what do we need to understand?
    Claudia PIONA, Claudia VENTRICI, Loredana MARCOVECCHIO, Francesco CHIARELLI, Claudio MAFFEIS, Riccardo BONFANTI, Ivana RABBONE
    Minerva Pediatrics, 2021
  • Type 1 diabetes prevalence and incidence rates in the pediatric population of Veneto Region (Italy) in 2015–2020
    Claudio Maffeis, Valentina Mancioppi, Claudia Piona, Francesco Avossa, Ugo Fedeli, Marco Marigliano
    Diabetes Research and Clinical Practice, 2021
  • Oxidative stress in youth with type 1 diabetes: Not only a matter of gender, age, and glycemic control
    Anita Morandi, Massimiliano Corradi, Silvia Orsi, Claudia Piona, Chiara Zusi, Silvia Costantini, Marco Marigliano, Claudio Maffeis
    Diabetes Research and Clinical Practice, 2021
  • Are we confident that final-year medical students know at least basics about diabetes?: A preliminary report from the multicenter, survey-based Diabetes Know-Me study
    Agata Chobot, Zuzanna Gosławska, Elisa Giani, Sirisha Kusuma Boddu, Malgorzata Mysliwiec, Rasha Odeh, Claudia Piona, Joanna Polanska, Meng‐Che Tsai, Carine Beaufort, Klemen Dovc, ISPAD JENIOUS
    Pediatric Diabetes, 2021
  • In vivo confocal microscopy study of corneal nerve alterations in children and youths with Type 1 diabetes
    Tiziano Cozzini, Claudia Piona, Giorgio Marchini, Tommaso Merz, Tommaso Brighenti, Jacopo Bonetto, Marco Marigliano, Francesca Olivieri, Claudio Maffeis, Emilio Pedrotti
    Pediatric Diabetes, 2021
  • Relationships between HbA1c and continuous glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children and adolescents with type 1 diabetes
    Claudia Piona, Marco Marigliano, Enza Mozzillo, Francesco Rosanio, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Elvira Piccinno, Maurizio Delvecchio, Claudio Maffeis
    Diabetes Research and Clinical Practice, 2021
  • Albuminuric and non-albuminuric reduced eGFR phenotypes in youth with type 1 diabetes: Factors associated with cardiometabolic risk
    Procolo Di Bonito, Enza Mozzillo, Francesco M. Rosanio, Giulio Maltoni, Claudia A. Piona, Roberto Franceschi, Carlo Ripoli, Maria R. Ricciardi, Gianluca Tornese, Claudia Arnaldi, Brunella Iovane, Dario Iafusco, Angela Zanfardino, Tosca Suprani, Silvia Savastio, Valentino Cherubini, Valentino Tiberi, Elvira Piccinno, Riccardo Schiaffini, Maurizio Delvecchio, Alberto Casertano, Claudio Maffeis, Adriana Franzese
    Nutrition Metabolism and Cardiovascular Diseases, 2021
  • Short-term effects of covid-19 lockdown in italian children and adolescents with type 1 diabetes mellitus: The role of separation anxiety
    Daniela Di Riso, Simone Bertini, Silvia Spaggiari, Francesca Olivieri, Silvana Zaffani, Lara Comerlati, Marco Marigliano, Claudia Piona, Claudio Maffeis
    International Journal of Environmental Research and Public Health, 2021
  • Delayed age at menarche in chronic respiratory diseases
    Rossella Gaudino, Sarah Dal Ben, Paolo Cavarzere, Sonia Volpi, Claudia Piona, Attilio Boner, Franco Antoniazzi, Giorgio Piacentini
    European Journal of Clinical Investigation, 2021
  • Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)
    Enza Mozzillo, Roberto Franceschi, Claudia Piona, Stefano Passanisi, Alberto Casertano, Dorina Pjetraj, Giulio Maltoni, Valeria Calcaterra, Vittoria Cauvin, Valentino Cherubini, Giuseppe D’Annunzio, Adriana Franzese, Anna Paola Frongia, Fortunato Lombardo, Donatella Lo Presti, Maria Cristina Matteoli, Elvira Piccinno, Barbara Predieri, Ivana Rabbone, Andrea Enzo Scaramuzza, Sonia Toni, Stefano Zucchini, Claudio Maffeis, Riccardo Schiaffini
    Frontiers in Endocrinology, 2021
  • Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function
    Claudia Piona, Sonia Volpi, Chiara Zusi, Enza Mozzillo, Antonella Tosco, Adriana Franzese, Valeria Raia, Maria Linda Boselli, Maddalena Trombetta, Marco Cipolli, Riccardo C Bonadonna, Claudio Maffeis
    Journal of Clinical Endocrinology and Metabolism, 2021
  • Long chain fatty acids metabolism and cardiovascular risk factors in youth with type 1 diabetes
    Anita Morandi, Claudia Piona, Sara Bonafini, Marco Marigliano, Francesca Tomasselli, Angela Tagetti, Denise Marcon, Silvia Costantini, Cristiano Fava, Claudio Maffeis
    Nutrition Metabolism and Cardiovascular Diseases, 2021
  • Central Systolic Blood Pressure Is Associated With Early Vascular Damage in Children and Adolescents With Type 1 Diabetes
    Angela Tagetti, Claudia A. Piona, Denise Marcon, Alice Giontella, Lorella Branz, Stefano Bortolotti, Anita Morandi, Claudio Maffeis, Cristiano Fava
    Frontiers in Cardiovascular Medicine, 2021
  • Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: Determination of optimal sampling duration
    Claudia Piona, Marco Marigliano, Enza Mozzillo, Adriana Franzese, Angela Zanfardino, Dario Iafusco, Giulio Maltoni, Stefano Zucchini, Maurizio Delvecchio, Claudio Maffeis
    Pediatric Diabetes, 2020
  • Cardiovascular risk factors in children and adolescents with type 1 diabetes in Italy: a multicentric observational study
    Elena Fornari, Claudia Piona, Ivana Rabbone, Francesca Cardella, Enza Mozzillo, Barbara Predieri, Donatella Lo Presti, Valentino Cherubini, Ippolita Patrizia Patera, Tosca Suprani, Riccardo Bonfanti, Vittoria Cauvin, Fortunato Lombardo, Stefano Zucchini, Angela Zanfardino, Elisa Giani, Petra Reinstadler, Nicola Minuto, Raffaele Buganza, Rosalia Roppolo, Marco Marigliano, Claudio Maffeis
    Pediatric Diabetes, 2020
  • 13C/12C breath test ratio after the ingestion of a meal naturally enriched with (13C)carbohydrates is a surrogate marker of insulin resistance and insulin sensitivity in children and adolescents with Type 1 Diabetes
    Marco Marigliano, Yves Schutz, Claudia Piona, Francesca Tomasselli, Mara Tommasi, Massimiliano Corradi, Francesca Olivieri, Elena Fornari, Anita Morandi, Claudio Maffeis
    Diabetes Research and Clinical Practice, 2020
  • Reduced minimum rim width of optic nerve head: a potential early marker of retinal neurodegeneration in children and adolescents with type 1 diabetes
    Claudia Piona, Tiziano Cozzini, Giorgio Marchini, Tommaso Merz, Tommaso Brighenti, Umberto Mazzo, Marco Marigliano, Francesca Olivieri, Emilio Pedrotti, Claudio Maffeis
    Diabetes Research and Clinical Practice, 2020
  • Nutrition habits of children and adolescents with type 1 diabetes changed in a 10 years span
    Claudio Maffeis, Francesca Tomasselli, Mara Tommasi, Irene Bresadola, Tatiana Trandev, Elena Fornari, Marco Marigliano, Anita Morandi, Francesca Olivieri, Claudia Piona
    Pediatric Diabetes, 2020
  • Systemic anti-oxidant capacity is inversely correlated with systolic blood pressure and pulse pressure in children with obesity
    Anita Morandi, Massimiliano Corradi, Claudia Piona, Elena Fornari, Rossella Puleo, Claudio Maffeis
    Nutrition Metabolism and Cardiovascular Diseases, 2020
  • Policaptil gel retard intake reduces postprandial triglycerides, ghrelin and appetite in obese children: A clinical trial
    Elena Fornari, Anita Morandi, Claudia Piona, Mara Tommasi, Massimiliano Corradi, Claudio Maffeis
    Nutrients, 2020
  • Skipping Breakfast Is Associated with an Atherogenic Lipid Profile in Overweight and Obese Prepubertal Children
    A. Blasetti, S. Franchini, V. Castorani, L. Comegna, E. Fornari, F. Daniele, G. Prezioso, C. Piona, V. Federico, D. Zona, I. Bresadola, F. Chiarelli, C. Maffeis
    International Journal of Endocrinology, 2020
  • Faster Compared with Standard Insulin Aspart during Day-And-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial
    Klemen Dovc, Claudia Piona, Gül Yeşiltepe Mutlu, Natasa Bratina, Barbara Jenko Bizjan, Dusanka Lepej, Revital Nimri, Eran Atlas, Ido Muller, Olga Kordonouri, Torben Biester, Thomas Danne, Moshe Phillip, Tadej Battelino
    Diabetes Care, 2020
  • Limb hypertrophy: A skin vascular malformation and bilateral hydroureteronephrosis in a neonate
    Grazia Morandi, Claudia Piona, Daniela Degani, May El Hachem, Nicoletta Resta, Carmela Richelli, Silvana Lauriola
    Archives of Disease in Childhood Education and Practice Edition, 2019
  • Vitamin D affects insulin sensitivity and β-cell function in obese non-diabetic youths
    Domenico Corica, Chiara Zusi, Francesca Olivieri, Marco Marigliano, Claudia Piona, Elena Fornari, Anita Morandi, Massimiliano Corradi, Emanuele Miraglia del Giudice, Davide Gatti, Maurizio Rossini, Riccardo C Bonadonna, Claudio Maffeis
    European Journal of Endocrinology, 2019
  • Non-adjunctive flash glucose monitoring system use during summer-camp in children with type 1 diabetes: The free-summer study
    Claudia Piona, Klemen Dovc, Gül Y. Mutlu, Klara Grad, Petra Gregorc, Tadej Battelino, Nataša Bratina
    Pediatric Diabetes, 2018
  • Minor diplotypes of FMO3 might protect children and adolescents from obesity and insulin resistance
    Anita Morandi, Chiara Zusi, Massimiliano Corradi, Francesca Olivieri, Claudia Piona, Elena Fornari, Claudio Maffeis
    International Journal of Obesity, 2018
  • Short stature and high serum transaminase levels: Growth hormone deficiency in a child with Becker muscular dystrophy
    Rossella Gaudino, Claudia Piona, Grazia Morandi, Evelina Maines, Claudia Banzato, Paola Tonin, Mauro Scarpelli, Paolo Cavarzere, Franco Antoniazzi
    Minerva Pediatrica, 2017
  • Glucose-independent association of adiposity and diet composition with cardiovascular risk in children and adolescents with type 1 diabetes
    Claudio Maffeis, Elena Fornari, Anita Morandi, Claudia Piona, Francesca Tomasselli, Mara Tommasi, Marco Marigliano
    Acta Diabetologica, 2017
  • Painless bilateral swelling of the face: Think about cherubism
    Claudia Piona, Evelina Maines, Grazia Morandi, Rossella Gaudino, Paolo Cavarzere, Ugo Consolo, Attilio Boner
    Archives of Disease in Childhood, 2015
  • Significant association among growing pains, vitamin D supplementation, and bone mineral status: results from a pilot cohort study
    Grazia Morandi, E. Maines, C. Piona, E. Monti, M. Sandri, R. Gaudino, A. Boner, F. Antoniazzi
    Journal of Bone and Mineral Metabolism, 2015